{
  "docId": "019de515-1bf5-75fc-a19f-ef7a3323e229",
  "docSlug": "a43786f91ea3b101a0e62521077ddab4",
  "documentTitle": "Adagio Therapeutics | Investor Conference Presentation Deck | 14 slides",
  "authorId": "adagio-therapeutics",
  "authorName": "Adagio Therapeutics",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 7,
  "pageCount": 14,
  "prevPage": 6,
  "nextPage": 8,
  "slideType": "propose_solution",
  "function": "propose_solution",
  "density": "dense",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 0.9,
  "imagePath": null,
  "slideHref": "/slides/019de515-1bf5-75fc-a19f-ef7a3323e229/7",
  "deckHref": "/decks/019de515-1bf5-75fc-a19f-ef7a3323e229",
  "deckJsonHref": "/decks/019de515-1bf5-75fc-a19f-ef7a3323e229.json",
  "deckAnchorHref": "/decks/019de515-1bf5-75fc-a19f-ef7a3323e229#slide-7",
  "components": [
    {
      "bbox": {
        "h": 0.52,
        "w": 0.39,
        "x": 0.54,
        "y": 0.28
      },
      "kind": "image",
      "text": null,
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ffa9b139-985d-4b31-90cf-5f6c810a0533",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.41,
        "w": 0.44,
        "x": 0.045,
        "y": 0.258
      },
      "kind": "list",
      "text": "VYD222 (Engineered from adintrevimab)\nDesigned for:\n• High potency\n• Lack of polyreactivity\n• Long half-life\n• Developability\n• Potential to resist escape\n• Target non-overlapping epitopes of spike RBD\n• Rare epitopes under less immune pressure\n• Conserved across human ACE2-using sarbecoviruses",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "da35c4b8-6d84-48c0-a83b-de0d36342728",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.59,
        "x": 0.045,
        "y": 0.728
      },
      "kind": "paragraph",
      "text": "VYD222 mAb candidate has demonstrated in vitro neutralizing activity against dominant variants of concern, including Omicron sub-lineages up to and through XBB.1.5",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "12e964f8-3b48-4c9b-a654-ba73b084bc7c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.16,
        "x": 0.045,
        "y": 0.915
      },
      "kind": "source-note",
      "text": "RBD, receptor binding domain\nVOC, variant of concern",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fe0ab81c-f2b7-43d4-bf4b-10644372a747",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.88,
        "x": 0.045,
        "y": 0.045
      },
      "kind": "title",
      "text": "SHOWCASE OF VYD222: ENGINEERED FOR BROAD ACTIVITY AND PROLONGED UTILITY",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4f730d8d-c998-4702-a899-2f8e852f3b3d",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 14,
      "from": 5,
      "beatId": "5e0a3ea5-562a-4e0c-9d61-b4223eb1f2a7",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "Slides 5-14 present Invivyd as a solution, detailing its approach, technology, and progress.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 14,
      "from": 5,
      "name": "Jobs To Be Done",
      "slug": "53-jobs-to-be-done",
      "bestFor": "Product innovation, market entry, competitive positioning",
      "matchId": "0486a116-46a3-4832-9ddb-898a5be96dc0",
      "evidence": "The loop is visible in how Invivyd's platform is positioned to meet treatment needs.",
      "position": 1,
      "objective": "Show how Invivyd addresses specific jobs or needs in COVID-19 treatment",
      "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit",
      "confidence": 0.6,
      "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}